NHS Scotland New Developer
- Acute leukaemia: proportion of patients with acute leukaemia 60 years of age and over receiving intensive chemotherapy who are enrolled in a clinical trial.
- Acute leukaemia: proportion of patients with acute leukaemia 60 years of age and over with performance status (PS) 0-1 who receive intensive chemotherapy.
- Acute leukaemia: proportion of patients with acute leukaemia being treated with curative intent who are enrolled in a clinical trial.
- Acute leukaemia: proportion of patients with acute leukaemia being treated with non-curative intent who are enrolled in a clinical trial.
- Acute leukaemia: proportion of patients with acute leukaemia between 16 and 65 years of age being treated with curative intent who have a specimen sent to the lab for tissue typing at diagnosis.
- Acute leukaemia: proportion of patients with acute leukaemia undergoing treatment with curative intent who die in first complete remission (CR), within 1 year of diagnosis.
- Acute leukaemia: proportion of patients with acute leukaemia undergoing treatment with curative intent who have complete diagnostic panel undertaken.
- Acute leukaemia: proportion of patients with acute leukaemia who are discussed at a multidisciplinary team (MDT) meeting within 6 weeks of diagnosis.
- Acute leukaemia: proportion of patients with acute leukaemia who have World Health Organisation (WHO) classification assigned and recorded (either by multidisciplinary team [MDT] or reporting haematologist/
haematopathologist). - Acute leukaemia: proportion of patients with acute lymphoblastic leukaemia (ALL) being treated with curative intent who die within 35 days of treatment.
- Acute leukaemia: proportion of patients with acute lymphoblastic leukaemia (ALL), less than 25 years of age, undergoing treatment with curative intent who are assessed for the presence of minimal residual disease (MRD) marker.
- Acute leukaemia: proportion of patients with acute myeloid leukaemia (AML) being treated with curative intent who die within 30 days of treatment.
- Acute leukaemia: proportion of patients with acute myeloid leukaemia (AML) who are suitable only for treatment with non-curative intent who receive palliative chemotherapy with either low dose cytarabine or azacytidine.
- Acute leukaemia: proportion of patients with acute promyelocytic leukaemia (APL) who receive all trans-retinoic acid (ATRA) within 1 day of diagnosis.
- Endometrial cancer: proportion of patients with endometrial cancer undergoing definitive surgery who undergo laparoscopic surgery.
- Endometrial cancer: proportion of patients with endometrial cancer who are discussed at a multidisciplinary team (MDT) meeting prior to definitive treatment.
- Endometrial cancer: proportion of patients with endometrial cancer who have an MRI and/or CT scan of the abdomen and pelvis prior to first treatment.
- Endometrial cancer: proportion of patients with endometrial cancer who undergo total hysterectomy (TH) and bilateral salpingo-oophorectomy (BSO).
- Endometrial cancer: proportion of patients with stage IB, grade 1 or 2, or stage IA, grade 3 endometrioid or mucinous endometrial cancer having adjuvant vaginal brachytherapy.
- Endometrial cancer: proportion of patients with stage IV endometrial cancer receiving chemotherapy.
- Ovarian cancer: proportion of epithelial ovarian cancer patients who receive platinum-based chemotherapy, either in combination or as a single agent.
- Ovarian cancer: proportion of patients with advanced epithelial ovarian cancer (FIGO stage 2 or higher) who have less than 1 cm macroscopic residual disease following surgery.
- Ovarian cancer: proportion of patients with advanced epithelial ovarian cancer (FIGO stage 2 or higher) who have no macroscopic residual disease following surgery.
- Ovarian cancer: proportion of patients with advanced epithelial ovarian cancer (FIGO stage 3c or 4) undergoing delayed primary surgery after neo-adjuvant chemotherapy where optimal cytoreduction is achieved (residual disease less than 1 cm).
- Ovarian cancer: proportion of patients with advanced epithelial ovarian cancer (FIGO stage 3c or 4) undergoing delayed primary surgery after neo-adjuvant chemotherapy.
- Ovarian cancer: proportion of patients with early stage epithelial ovarian cancer (FIGO stage 1) undergoing primary surgery and operated on by a gynaecological oncologist, who have an adequate staging operation involving total abdominal hysterectomy (TAH), bilateral salpingo-oophorectomy (BSO), omentectomy and washings.
- Ovarian cancer: proportion of patients with early stage epithelial ovarian cancer (FIGO stage 1) undergoing primary surgery who have an adequate staging operation involving total abdominal hysterectomy (TAH), bilateral salpingo-oophorectomy (BSO), omentectomy and washings.
- Ovarian cancer: proportion of patients with epithelial ovarian cancer having a CT scan or MRI of the abdomen and pelvis performed prior to starting definitive treatment.
- Ovarian cancer: proportion of patients with epithelial ovarian cancer having a histo/cytological diagnosis recorded prior to starting neo-adjuvant chemotherapy with confirmation obtained by histology.
- Ovarian cancer: proportion of patients with epithelial ovarian cancer having a histo/cytological diagnosis recorded prior to starting neo-adjuvant chemotherapy.
- Ovarian cancer: proportion of patients with epithelial ovarian cancer undergoing definitive cytoreductive surgery having a complete pathology report as defined by the Royal College of Pathologists.
- Ovarian cancer: proportion of patients with epithelial ovarian cancer who are discussed at a multidisciplinary team (MDT) meeting before definitive treatment.
- Ovarian cancer: proportion of patients with stage 1 epithelial ovarian cancer having Risk of Malignancy Index (RMI) assessed and recorded in their notes prior to any definitive surgical intervention.
No hay comentarios:
Publicar un comentario